Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

ABSTRACT:

Background

Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy.

Methods

In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed CML in the chronic phase to receive either imatinib or interferon alfa plus cytarabine. Long-term analyses included overall survival, response to treatment, and serious adverse events.

Results

The median follow-up was 10.9 years. Given the high rate of crossover among patients who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and

SUBMITTER: Hochhaus A 

PROVIDER: S-EPMC5901965 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature